Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

25.00
-0.4550-1.79%
Volume:4.21K
Turnover:105.88K
Market Cap:687.38M
PE:-9.30
High:25.29
Open:25.29
Low:24.93
Close:25.45
Loading ...

Aquestive Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Mar

Prelude Therapeutics FY Sales $7.000M Beat $2.000M Estimate

Benzinga
·
10 Mar

Trevi Therapeutics Says Phase 2a Haduvio Trial Shows Significant Reduction in Cough Count

MT Newswires Live
·
10 Mar

William Blair Downgrades Neumora Therapeutics to Market Perform From Outperform

MT Newswires Live
·
10 Mar

Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)

TIPRANKS
·
10 Mar

Prelude Therapeutics sees cash runway into 2Q26

TIPRANKS
·
10 Mar

Trevi Therapeutics upgraded to Strong Buy from Outperform at Raymond James

TIPRANKS
·
10 Mar

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement

GlobeNewswire
·
10 Mar

Press Release: Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Dow Jones
·
10 Mar

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

GlobeNewswire
·
10 Mar

Citigroup Upgrades ProQR Therapeutics to Buy From Neutral, Price Target is $4

MT Newswires Live
·
10 Mar

Design Therapeutics Q4 2024 GAAP EPS $(0.24) Beats $(0.28) Estimate

Benzinga
·
10 Mar

Trevi Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
10 Mar

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
10 Mar

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
10 Mar

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

GlobeNewswire
·
10 Mar